|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
57,860,000 |
Market
Cap: |
322.86(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.47 - $6.68 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 14.8 |
Insider 3/6 Months : 15.4 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Aldeyra Therapeutics is a biotechnology company focused on discovering and developing therapies designed to treat immune-mediated diseases. Co.'s primary product candidate, reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. Co. has additional product candidates in development for autoimmune diseases and other immune-mediated disease, as well as for proliferative vitreoretinopathy (PVR) and other retinal diseases. Co. has rights to ADX-2191, a vitreous-compatible methotrexate formulation for intraocular injection, for the prevention of PVR, a retinal disease, and primary vitreoretinal lymphoma, a rare cancer.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
682,265 |
682,265 |
682,265 |
Total Buy Value |
$0 |
$2,768,372 |
$2,768,372 |
$2,768,372 |
Total People Bought |
0 |
1 |
1 |
1 |
Total Buy Transactions |
0 |
5 |
5 |
5 |
Total Shares Sold |
26,875 |
26,875 |
3,034,319 |
3,034,319 |
Total Sell Value |
$127,288 |
$127,288 |
$5,386,399 |
$5,386,399 |
Total People Sold |
2 |
2 |
4 |
4 |
Total Sell Transactions |
2 |
2 |
11 |
11 |
End Date |
2024-06-23 |
2024-03-22 |
2023-09-22 |
2022-09-22 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Edelman Joseph |
10% Owner |
|
2022-08-03 |
4 |
B |
$5.84 |
$584,000 |
I/I |
100,000 |
10,901,985 |
1.5 |
7% |
|
Edelman Joseph |
10% Owner |
|
2022-08-02 |
4 |
B |
$5.59 |
$2,305,350 |
I/I |
412,406 |
10,801,985 |
1.5 |
12% |
|
Edelman Joseph |
10% Owner |
|
2022-08-01 |
4 |
B |
$5.05 |
$728,134 |
I/I |
144,185 |
10,389,579 |
1.5 |
22% |
|
Edelman Joseph |
10% Owner |
|
2022-07-29 |
4 |
B |
$5.03 |
$1,117,279 |
I/I |
222,123 |
10,245,394 |
1.5 |
22% |
|
Edelman Joseph |
10% Owner |
|
2022-07-28 |
4 |
B |
$5.00 |
$596,960 |
I/I |
119,392 |
10,023,271 |
1.5 |
22% |
|
Machatha Stephen |
Chief Development Officer |
|
2022-07-15 |
4 |
A |
$0.00 |
$0 |
D/D |
185,605 |
273,263 |
|
- |
|
Greenberg Bruce |
See Remarks |
|
2022-07-15 |
4 |
A |
$0.00 |
$0 |
D/D |
126,087 |
133,900 |
|
- |
|
Joyce Martin Joseph |
Director |
|
2022-06-23 |
4 |
B |
$3.48 |
$15,025 |
D/D |
4,323 |
23,967 |
2.39 |
- |
|
Brady Todd C |
President and CEO |
|
2022-06-23 |
4 |
B |
$3.36 |
$59,546 |
D/D |
17,700 |
1,216,535 |
2.81 |
- |
|
Greenberg Bruce |
See RemarksOfficer |
|
2022-05-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,813 |
|
- |
|
Machatha Stephen |
Chief Development Officer |
|
2022-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
64,395 |
87,658 |
|
- |
|
Brady Todd C |
President and CEO |
|
2022-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
1,198,835 |
|
- |
|
Reed Joshua |
Chief Financial Officer |
|
2022-03-30 |
4 |
A |
$0.00 |
$0 |
D/D |
93,322 |
274,825 |
|
- |
|
Edelman Joseph |
10% Owner |
|
2021-05-03 |
4 |
B |
$12.50 |
$15,000,000 |
I/I |
1,200,000 |
9,903,879 |
1.5 |
- |
|
Brady Todd C |
President and CEO |
|
2021-04-12 |
4 |
A |
$0.00 |
$0 |
D/D |
46,619 |
948,835 |
|
- |
|
Edelman Joseph |
10% Owner |
|
2021-01-19 |
4 |
B |
$9.50 |
$13,000,000 |
I/I |
1,368,421 |
8,703,879 |
1.5 |
- |
|
Edelman Joseph |
10% Owner |
|
2021-01-08 |
4 |
B |
$7.60 |
$5,137,668 |
I/I |
550,000 |
7,335,458 |
1.5 |
- |
|
Edelman Joseph |
10% Owner |
|
2021-01-07 |
4 |
B |
$8.13 |
$4,065,000 |
I/I |
500,000 |
6,785,458 |
1.5 |
- |
|
Machatha Stephen |
Chief Development OfficerOffic |
|
2020-12-08 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
211 |
|
- |
|
Machatha Stephen |
Chief Development OfficerOffic |
|
2020-12-08 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
20,091 |
|
- |
|
Douglas Richard |
Director |
|
2020-03-16 |
4 |
B |
$2.75 |
$110,000 |
D/D |
40,000 |
125,000 |
2.39 |
- |
|
Reed Joshua |
Chief Financial Officer |
|
2020-03-02 |
4/A |
A |
$0.00 |
$0 |
D/D |
137,707 |
173,481 |
|
- |
|
Mcmullin David |
Chief Commercial Officer |
|
2020-03-02 |
4/A |
A |
$0.00 |
$0 |
D/D |
247,480 |
255,183 |
|
- |
|
Reed Joshua |
Chief Financial Officer |
|
2020-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
285,774 |
|
- |
|
Mcmullin David |
Chief Commercial Officer |
|
2020-03-02 |
4 |
A |
$0.00 |
$0 |
D/D |
250,000 |
257,703 |
|
- |
|
96 Records found
|
|
Page 2 of 4 |
|
|